Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Body Approves Novartis's Tasigna For CML

04/24/2012 | 07:16pm US/Eastern

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

React to this article
Latest news on NOVARTIS AG
09/04 AMGEN : Joins Forces with Novartis for Alzheimer's Disease and Migraine Programs
09/04 NOVARTIS : receives EU approval for Farydak®, the first in its class of anticanc..
09/03DJNovartis to Begin Selling Copy of Amgen's Neupogen in U.S.--3rd Update
09/03DJEUROPE MARKETS : European Stocks End Higher As ECB's Mario Draghi Talks More Eas..
09/03DJEUROPE MARKETS : European Stocks Charge Higher On Hopes For More Eurozone Stimul..
09/03DJEUROPE MARKETS : European Markets Rise; Investors Wait For QE Hints From Draghi
09/03DJNovartis to Begin Selling Copy of Amgen's Neupogen in U.S. -- Update
09/03DJEUROPE MARKETS : European Markets Rise, As Investors Wait For QE Hints From Drag..
09/03DJNovartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/03DJNovartis to Begin Selling Copy of Amgen's Neupogen in US
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
More Financials